

Product Information

Glutathione-Agarose

Lyophilized powder

G4510

Product Description

Affinity chromatography with glutathione-agarose permits rapid, mild, non-denaturing and highly selective purification of glutathione-binding enzymes,¹⁻⁴ such as glutathione-S-transferase, glutathione peroxidase, and glyoxalase I.

This product consists of glutathione attached through its sulfur to epoxy-activated 4% cross-linked beaded agarose, resulting in a 12-atom (10-carbon) spacer. Glutathione-Agarose is provided as a lyophilized powder stabilized with lactose. Lactose is added as a stabilizer to prevent bead fracture. One gram of powder swells to 10.5-16.0 mL of gel (~70 mg of powder swells to 1 mL of gel).

Several publications,⁵⁻¹⁵ theses,¹⁶⁻²¹ and dissertations²²⁻⁴² have cited use of this G4510 product in their protocols.

Product Profile

- Ligand: 10 to 30 μ moles per mL swollen resin
- Binding capacity: 5-10 mg glutathione S-transferase per mL resin

Storage/Stability

If stored properly desiccated at $-20\text{ }^{\circ}\text{C}$, the product has a shelf life of two years. If exposed to heat and moisture, the beads may not swell properly, or may not be active.

After the resin has been swollen, it can be stored in 2 M NaCl at 2-8 $^{\circ}\text{C}$. For long-term storage, a bacteriostatic agent, such as 1 mM sodium azide, should be included. Alternatively, the resin can be re-lyophilized after the addition of lactose.

Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

Preparation Instructions

Glutathione-Agarose gel

- Swell the lyophilized powder in water at 200 mL/g. (Use of some buffers can result in non-recoverable loss of volume.)
- Typically, 90-95% of swelling occurs within 30 minutes at room temperature. However, it may require overnight at 2-8 $^{\circ}\text{C}$ for 100% swelling to occur.
- After swelling, the agarose beads must be washed thoroughly with 10 volumes of water or Equilibration Buffer (such as PBS), to remove the lactose present in the lyophilized product.

Buffers and Other Reagents

- Equilibration Buffer: Phosphate buffered saline (PBS, such as Cat. No. P3813), 10 mM phosphate buffer, pH 7.4, 150 mM NaCl. Add appropriate protease inhibitors when preparing cell lysate.
- TRITON™ X-100: Cat. No. T9284
- PBS containing 1% TRITON™ X-100
- Elution Buffer: 5-10 mM reduced glutathione (Cat. No. G4251) in 50 mM Tris-HCl (pH 9.5 \pm 0.1 at 4 $^{\circ}\text{C}$, or pH 9.0 at 25 $^{\circ}\text{C}$).
- Cleansing Buffer 1: 0.1 M borate buffer, pH 8.5, containing 0.5 M NaCl. Prepare using boric acid (Cat. No. B0394). Adjust pH with NaOH.
- Cleansing Buffer 2: 0.1 M acetate buffer, pH 4.5, containing 0.5 M NaCl. Prepare acetate buffer using sodium acetate (such as Cat. No. 236500). Adjust pH with acetic acid (such as Cat. No. 695092).
- Storage Buffer: 2 M NaCl containing 1 mM sodium azide as preservative

Procedure

Glutathione-agarose may be used in column or batch purifications. This procedure may be used as a guideline for column purification. For batch purifications, use low speed centrifugation (10 seconds at 200-500 × *g*) to pellet the beads, and decant between steps.

Column Set-Up

1. Prepare resin as described in the Preparation Instructions.
2. De-aerate the resin. Carefully pour the slurry into the column, avoiding the introduction of air bubbles.
3. After the resin has been packed in the column, equilibrate the resin with several column volumes of Equilibration Buffer. Do not let the column run dry at any time.

Purification of GST

1. Prepare cell lysate in appropriate buffer.
 - Tris or phosphate buffers, pH 6.5-9.5, are typical lysis buffers compatible with glutathione affinity chromatography.
 - Salt concentrations of up to 1 M do not interfere with binding.
 - Protease inhibitors such as EDTA (such as Cat. No. E7889) or PMSF (Cat. No. P7626) are often included in the lysis buffer. Serine protease inhibitors included in the lysis buffer will not interfere with subsequent thrombin or factor Xa treatment, as these inhibitors are removed before the proteolysis step.
 - The binding of GST to glutathione-agarose is unaffected by 1% TRITON™ X-100, 1% CTAB, 1% TWEEN®-20, 10 mM DTT, or 0.03% SDS.
2. Add TRITON™ X-100 to a final concentration of 1% (v/v).
3. Centrifuge 10 minutes at 10,000 × *g* at 4 °C, or filter through a 0.45 µm filter to clear cell lysate.

Note: Use only clarified supernatant. To prevent clogging the column, highly viscous samples containing chromosomal DNA or RNA should be sonicated or treated with nuclease to reduce the viscosity. Cellular debris and particulate matter must be removed by centrifugation or filtration.
4. Load the clarified supernatant onto the column under gravity flow.

Note: Depending on the sample and the flow rate, not all the protein may bind. Multiple passes over the column or closing the loaded column and incubating it on a rotator, may improve the binding efficiency.

For batch purification, add 2 mL of glutathione-agarose (50% v/v) in Equilibration Buffer to an appropriate amount of clarified supernatant. Incubate sample with glutathione-agarose with gentle mixing for 5-30 minutes at 4 °C.

5. Wash resin four times with PBS-T at 4 °C.
6. Elute GST from the resin with Elution Buffer (3 times, 1 mL each). For batch purification, mix each elution step gently for 2 minutes.
7. Analyze each fraction by SDS-PAGE.
8. Free glutathione may be removed from sample by dialysis against buffer of choice.

Column Cleaning

1. Wash with ~5 resin volumes of Cleansing Buffer 1.
2. Wash with at least 5 column volumes of water.
3. Wash with at least 5 column volumes of Cleansing Buffer 2.
4. Wash with ~5 resin volumes of water. For long-term storage, store in 2 M NaCl containing a bacteriostatic agent.
5. Equilibrate with Equilibration Buffer before use.

References

1. Simons, P.C., and Vander Jagt, D.L., *Anal. Biochem.*, **82(2)**, 334-341 (1977).
2. Simons, P.C., and Vander Jagt, D.L., *Methods Enzymol.*, **77**, 235-237 (1981).
3. Scopes, R., in *Protein Purification, Principles & Practice*. Springer-Verlag (New York, NY), pp. 30, 34 (1982).
4. Toribio, F. *et al.*, *J. Chromatogr. B. Biomed. Appl.*, **684(1-2)**, 77-97 (1996).
5. Shepherd, P.S. *et al.*, *J. Gen. Virol.*, **73(Pt 5)**, 1269-1274 (1992).
6. Mortlock, D.P. *et al.*, *Genome Res.*, **6(4)**, 327-335 (1996).
7. Kapranov, P. *et al.*, *Proc. Nat. Acad. Sci. USA*, **96(4)**, 1738-1743 (1999).
8. Tu, S.L. *et al.*, *J. Am. Chem. Soc.*, **126(28)**, 8682-8693 (2004).
9. Jain, M., and Cox, J.S., *PLoS Pathog.*, **1(1)**, e2 (2005).
10. Tu, S.-L. *et al.*, *J. Biol. Chem.*, **281(6)**, 3127-3136 (2006).
11. Whalen, K.E. *et al.*, *Arch. Biochem. Biophys.*, **478(1)**, 7-17 (2008).
12. LaCourse, E.J. *et al.*, *Environ. Pollut.*, **157(8-9)**, 2459-2469 (2009).

13. Benschop, J.J. *et al.*, *Mol. Cell*, **38(6)**, 916-928 (2010).
14. Das, A. *et al.*, *Nat. Cell Biol.*, **14(3)**, 304-310 (2012).
15. Li, X. *et al.*, *Cell Rep.*, **36(12)**, 109706 (2021).
16. Curman, Darko, "An Investigation of the G2 Checkpoint". University of British Columbia, M.Sc. thesis, p. 28 (1999).
17. Vaz, Jerusha C., "Purification, Characterization, and Active Site Studies of 2-(2'-Hydroxyphenyl) Benzenesulfinate Desulfinate (Dszb) From *Nocardia asteroides* Sp. Strain A3H1". Texas State University – San Marcos, M.S. thesis, p. 66 (December 2009).
18. Marek, Adam Robert, "Determination of An Interaction between Nipped B-Like Protein and MLL". Loyola University Chicago, M.S. thesis, p. 22 (August 2012).
19. Capota, Emanuela, "The Role of S-Adenosylmethionine Synthetase in Killing Effects of DFMO in African Trypanosomes". University of Texas Southwestern Medical Center at Dallas, M.S. thesis, p. 15 (August 2012).
20. Simões, Marco Aurélio Dias, "Crosstalk Between Energy and Gibberellin Signaling Pathways - A Molecular Approach". Instituto Politécnico de Leiria, M.Sc. thesis, p. 21 (2015).
21. Erb, Michael, "Characterizing the Transcriptional Regulation and Role of the Growth Arrest Specific P20k Lipocalin in Chicken Embryo Fibroblasts". McMaster University, M.Sc. thesis, p. 39 (August 2016).
22. Hinshelwood, Justin, "Structural Studies of factor B of the Alternative Pathway of the Complement System". University College London, Ph.D. dissertation, pp. 97, 158, 301 (May 2000).
23. Taylor, Michele Parker, "The effects of genetic and luminal risk factors on cyclooxygenase-2 expression in human colon cancer cells". University of Arizona, Ph.D. dissertation, p. 49 (2002).
24. Copley, LaRae Meschelle, "Investigation of the Function of Myotubularin Through Examination of Protein-Protein Interactions and Exclusion of Mtmr1 as a Frequent Cause of X-Linked Myotubular Myopathy". The Ohio State University, Ph.D. dissertation, p. 56 (2004).
25. Steels, Jonathan David, "Probing Septin Function Through Interaction Screens: Identification of Novel Septins and Possible Regulatory Mechanisms". University of Toronto, Ph.D. dissertation, p. 58 (2008).
26. Cook, Peter Joseph, "Eya: A Dual Function Nuclear Factor Crucial for Regulation of Developmental Gene Expression and Prevention of Apoptosis in Response to Genotoxic Stress". University of California San Diego, Ph.D. dissertation, p. 51 (2009).
27. Lai, Huiguo, "Interactions of Quinolins, Peptides and SNAP-25 with the Protease Domain of Botulinum Neurotoxin A". Georgetown University, Ph.D. dissertation, p. 30 (September 2010).
28. Smith, Jeffery R., "The Role of Rho GTPases in Breast Cancer Progression". Memorial Sloan-Kettering Cancer Center, Ph.D. dissertation, p. 37 (November 2012).
29. Kumar Sama, Reddy Ranjith, "FUS/TLS in Stress Response - Implications for Amyotrophic Lateral Sclerosis". University of Massachusetts Chan Medical School, Ph.D. dissertation, p. 122 (2014).
30. Chatterjee, Mandovi, "Regulation of the Ran GTPase System and Nucleocytoplasmic Transport". University of Virginia, Ph.D. dissertation, p. 94 (December 2014).
31. Huang, Yizhou, "Characterisation and Functional Validation of ERG Phosphorylation in Normal Haematopoietic and Leukaemic Cells". University of New South Wales, Ph.D. dissertation, pp. 85, 266 (September 2015).
32. Burns, Erin Elizabeth, "Genetic and Physiological Characterization and Ecological Management of Non-Target Site Resistance in Multiple Herbicide Resistant *Avena Fatua* L.". Montana State University, Ph.D. dissertation, p. 48 (2017).
33. Martinckus, Antons, "Role of STAT3 N-terminal domain and GAS-site recognition in signaling and crosstalk with STAT1 and NF-κB". RWTH Aachen University, Ph.D. dissertation, p. 56 (2017).
34. Wu, Jheng-Yu, "Regulation of Extracellular Signal-Regulated Kinase by Histone Deacetylase 6". University of South Florida, Ph.D. dissertation, p. 22 (2017).
35. Barton, Rachael, "Mechanisms of cohesin protection and removal during meiosis in *Saccharomyces cerevisiae*". University of Edinburgh, Ph.D. dissertation, p. 233 (2018).
36. Wang, Xiaomeng, "Investigation of the role of mTORC1 and MAPK/ERK pathways in cellular responses to amino acid deprivation". University of Liverpool, Ph.D. dissertation, p. 73 (July 2018).
37. Mitxitorena, Izaskun, "*In vitro* studies on the recognition of NF-κB p65 subunit by the deubiquitinase enzyme USP7". University of Glasgow, Ph.D. dissertation, pp. 94, 108 (September 2018).

38. Darell, Janne Evjen, "Identification of novel interactions between the proline-rich motif on Receptor Tyrosine Kinases and the SH3 domain of cytoplasmic proteins under non-stimulated condition". University of Leeds, Ph.D. dissertation, p. 33 (November 2018).
39. Adamo, Mattilo Carmelo, "Regulation of plant energy signaling by components of the abscisic acid pathway". Universidade Nova de Lisboa, Ph.D. dissertation, p. 112 (2019).
40. Estabrooks, Samuel Kenneth, "Reconstitution of CFTR Ubiquitination and Endoplasmic Reticulum Quality Control". University of Pittsburgh, Ph.D. dissertation, p. 53 (2020).
41. Tripathi, Soma, "The Smad7 protein interaction network in skeletal myogenesis". York University, Ph.D. dissertation, pp. 49, 156 (September 2020).
42. Livermore, Karen Elizabeth, "Identification and characterisation of novel mechanisms affecting prostate cancer cell growth". Newcastle University, Ph.D. dissertation, p. 62 (November 2020).

Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

Technical Assistance

Visit the tech service page at SigmaAldrich.com/techservice.

Standard Warranty

The applicable warranty for the products listed in this publication may be found at SigmaAldrich.com/terms.

Contact Information

For the location of the office nearest you, go to SigmaAldrich.com/offices

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, Millipore, MILLIPLEX and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

G4510bul Rev 01/22 GCY,MCH,MAM

The logo for MilliporeSigma, featuring the word "MILLIPORE" in a blue, sans-serif font above the word "SIGMA" in a larger, bold, blue, sans-serif font.